{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-013552","form_type":"8-K","ticker":"ESPR","cik":"0001434868","company_name":"Esperion Therapeutics, Inc.","filed_at":"2026-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.075752+00:00","generated_at":"2026-05-15T22:12:41.817937+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Esperion to acquire Corstasis for $75M upfront; adds Enbumyst nasal spray for heart failure edema","bullets":["Esperion acquires Corstasis for $75M cash upfront; up to $180M in milestones plus low double-digit royalties on Enbumyst sales.","Enbumyst (bumetanide nasal spray) is first FDA-approved nasal spray diuretic for edema in CHF, hepatic, renal disease (approved Sep 2025).","Esperion expects to leverage its cardiovascular commercial infrastructure to drive double-digit revenue growth; addresses $4B+ U.S. market.","Transaction financed via existing credit facilities and royalty monetization; expected close Q2 2026.","Corstasis also developing subcutaneous multidose pen injector; complements Esperion's pipeline in metabolic, hepatic, renal disease."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-013552","json":"https://secwatch.observer/filing/0001628280-26-013552.json","markdown":"https://secwatch.observer/filing/0001628280-26-013552.md","text":"https://secwatch.observer/filing/0001628280-26-013552.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434868/000162828026013552/0001628280-26-013552-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434868/000162828026013552/espr-20260302.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T22:12:41.817937+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"329107c91cdbed0a68c62095c3e401810e4a6323","claim":"Esperion Therapeutics, Inc. entered into Agreement and Plan of Merger with Corstasis Therapeutics Inc., a Delaware corporation (“Corstasis”), and Cirrus Transaction Subsidiary, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“Merger Sub”) valued at $75,000,000 (effective 2026-03-02).","evidence_excerpt":"On March 2, 2026, Esperion Therapeutics, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Corstasis Therapeutics Inc., a Delaware corporation (“Corstasis”), and Cirrus Transaction Subsidiary, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“Merger Sub”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828026013552/0001628280-26-013552-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Corstasis Therapeutics Inc., a Delaware corporation (“Corstasis”), and Cirrus Transaction Subsidiary, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“Merger Sub”)"},{"label":"Value","value":"$75,000,000"},{"label":"Effective","value":"2026-03-02"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}